Clinical Trials | A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)

The University of Virginia seeks adults ages 18 and over with early stage breast cancer with estrogen receptor (ER)-positive, HER2 negative tumors. This study is testing if adding chemotherapy to treatment with ovarian function suppression (OFS) and hormone therapy (ET) helps women with early-stage, estrogen receptor-positive breast cancer live longer without their cancer coming back. You may be eligible for this study if: - You are premenopausal at the time of pre-entry - Your tumor is both ER positive and HER2-negative This study involves blood draw, physical examination, and Mammogram or MRI. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: Study Details | Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | ClinicalTrials.gov